Matching slides 303,780
Current window 202,351-202,380
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

202,351-202,380 of 303,780

filter-aware
12
The slide outlines a clinical trial protocol using a sequential phase design.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide features a person sitting on a rock overlooking a landscape, with the company logo on their jacket.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The slide provides a scientific foundation for the CLDN6xCD3 bispecific antibody program.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide highlights CLDN6 in the context of the CLDN family tree.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The slide uses a list-based structure to present three key pillars of the target's clinical profile.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
The table highlights the prevalence column with an orange box.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
18
The slide illustrates the modular assembly of a bispecific antibody from two distinct components.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
The charts show dose-response curves where the proprietary antibodies (IM301, IM302) maintain high binding to CLDN6 while showing minimal off-target binding compared to the benchmark.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
The slide compares the library against a benchmark (IMAB027) in terms of reactivity and cytotoxicity.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide features a person sitting on a mountain peak, which is a common visual metaphor for vision or future outlook.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
Context Therapeutics | Investor Presentation Deck | 25 slidesContext Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
The slide uses a timeline format to track progress of two distinct drug development programs.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
Context Therapeutics | Investor Presentation Deck | 25 slidesContext Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
Context Therapeutics | Investor Presentation Deck | 25 slidesContext Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
Exhibit 99.1 indicates this is likely a public filing or investor relations document.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Setup1 hit
02
CTI BioPharma | Investor Presentation Deck | 24 slidesCTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Setup1 hit
03
Slide provides a snapshot of product approval, financial performance, and market opportunity.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · SetupLoop · Golden Circle1 hit
04
Includes market sizing data and clinical characteristics of the target patient segment.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a combination of real-world dosing data and HCP satisfaction surveys to argue that the current standard of care (Jakafi) is being used ineffectively, creating a market need.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
07
Includes product packaging imagery and regulatory status summary.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations 1 hit
09
The slide outlines a randomized controlled trial design for Myelofibrosis treatment.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
10
The slide uses a process flow diagram to represent clinical trial methodology.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
11
Includes two charts: a bar chart for SVR achievement and a waterfall plot for median percentage change in spleen volume.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
12
Includes a bar chart for response rates and a waterfall plot for individual patient symptom changes.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
13
The slide uses three bar charts to illustrate clinical efficacy endpoints related to anemia in a specific patient population.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
14
Data presented as median values with interquartile ranges (IQR).CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
15
The slide presents data from a retrospective analysis of the PERSIST-2 trial.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations 1 hit
16
The slide uses a biological process diagram to explain the mechanism of action.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations 1 hit
17
The slide compares two different clinical trial datasets (PERSIST-2 vs MOMENTUM) to highlight efficacy.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations 1 hit
18
CTI BioPharma | Investor Presentation Deck | 24 slidesCTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Go-to-MarketLoop · Quick Win Big Bet1 hit